Identity
- Security key
- 21058
- Ticker
- RNA
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2026-02-27
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- RNA
Detail
Enriched 2026-08-14 20:47
- Market cap
- $208,175,675.31
- Shares outstanding (class)
- 17,105,643
- Shares outstanding (weighted)
- 17,105,643
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 391
- Location
- SAN DIEGO, CA
- Description
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.